Get the latest AbbVie Inc. (ABBV) stock price, news, buy or sell recommendation, and investing advice from Wall Street professionals.
Current Price $461.76 NASDAQ: ILMN Illumina Market Cap $20B Current Price $126.15 NASDAQ: GILD Gilead Sciences Market Cap $102B Current Price $82.21 NASDAQ: EXEL Exelixis Market Cap $7B Current Price $26.06 Premium Investing Services Invest better with The Motley Fool. Get stock recommendations,...
Why AbbVie (ABBV) Outpaced the Stock Market Today (Zacks) 12:05PM 3 Things You Need to Know if You Buy AbbVie Stock Today (Motley Fool) 09:00AM AbbVie Showcases Advancement of Solid Tumor Pipeline at ESMO 2024, with New Data in Tumor Types with High Unmet Needs ...
Wolf: $ABBV IRA #Bottom-Fishing Buy-write stock 160 06/28 STO160 call @ 3.79. BTC today @ 2.08. Wolf: $ABBV making a dragonfly off the 200DMA. NP. indigo1948: @DAN $ADBE - Dan - good morning. Could you cover $ABBV, $SANM, $DOCU and $CLF. Thank you. ...
Currently, the analyst consensus on AbbVie is a Strong Buy with an average price target of $186.17, implying a 16.7% upside from current levels. In a report issued on April 26, Bank of America Securities also reiterated a Hold rating on the stock with a $...
Looking for a portfolio of ideas like this one? Members of The Data Driven Investor get exclusive access to our model portfolio.Get started today » AbbVie's (NYSE:ABBV) stock is under pressure due to the fact that the patent for Humira will be expiring in 2023, and this is a major...
recommended for you about abbv stock symbol last price % chg 1d 5d 1m 6m 1y 5y 10y market cap pe yield rev growth (yoy) short interest prev. close compare to peers more on abbv related stocks symbol last price % chg abbv abbv - - 1d 5d 1m 6m 1y 5y 10y compare trending analysis ...
AbbVie is announcing today that its board of directors declared an increase in the company’s quarterly cash dividend from $1.48 per share to $1.55 per share beginning with the dividend payable on February 15, 2024 to shareholders of record as of January 16, 2024. This reflects an increase ...
AbbVie(ABBV) surged out of the gate following its January 2013 spinoff from Abbott Laboratories(ABT). By December 2014, the stock price had doubled. Since then, however, the stock languished, continuing to trade below its December 2014 highs. Despite efforts to diversify, Humira, which is ...
*Stock Advisor returns as of January 29, 2024 These non-GAAP financial measures are reconciled with comparable GAAP financial measures in our earnings release and regulatory filings from today, which can be found on our website. In addition to the news release issued this morning, we have ...